Skip to main content

From the helm: Proteomics International (ASX:PIQ), Dr. Richard Lipscombe, Managing Director

Bell Direct
July 7, 2025

In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.

In this video, Dr. Lipscombe covers:
·      (0:47): An overview of PIQ and its FY26 goals
·      (1:38): The significance of three world-first blood tests
·      (5:26): The global addressable markets for these conditions
·      (6:25): Clinical trial progress and commercialisation roadmap
·      (8:14): How the diagnostic tests work and deliver value to patients
·      (9:16): Commercialisation strategy across key regions
·      (11:23): Additional assets in the PIQ pipeline
·      (12:36): What investors can expect over the next 12 months

Note: This interview was recorded on 3 July 2025.

Market Update

Bell Direct
April 18, 2017

Market Update

Bell Direct
April 13, 2017

Market Update

Bell Direct
April 12, 2017

Market Update

Bell Direct
April 11, 2017

Market Update

Bell Direct
April 10, 2017

Market Update

Julia Lee
April 7, 2017

Market Update

Julia Lee
April 6, 2017

Market Update

Julia Lee
April 5, 2017

Market Update

Julia Lee
April 4, 2017

Market Update

Julia Lee
April 3, 2017

Market Update

Julia Lee
March 31, 2017

Market Update

Julia Lee
March 30, 2017